| Home  | About ScienceAsia  | Publication charge  | Advertise with us  | Subscription for printed version  | Contact us  
Editorial Board
Journal Policy
Instructions for Authors
Online submission
Author Login
Reviewer Login
Volume 50 Number 1
Volume 49 Number 6
Volume 49 Number 5
Volume 49S Number 1
Volume 49 Number 4
Volume 49 Number 3
Earlier issues
Volume  Number 

previous article next article

Research articles

ScienceAsia 49 (2023):ID 653-660 |doi: 10.2306/scienceasia1513-1874.2023.066


Celastrol attenuates interleukin-8 release from LPS-activated human monocytes and monocyte-derived macrophages by inhibiting the NF-κB signalling pathway


Nipapan Malisorna,*, Wannapa Bootkotra, Thassapong Khamkhaia, Ammara Chaikana, Supawadee Seubsasanab

 
ABSTRACT:     Interleukin-8 (IL-8), a potent neutrophil chemotactic factor, plays a critical role during inflammation. IL-8 is produced primarily by several immune cell types upon lipopolysaccharide (LPS) stimulation by activating the nuclear factor-?B (NF-?B) signalling pathway. NF-?B is an important transcription factor implicated in the inflammatory response, and the NF-?B signalling pathway is a potential target for inhibition by anti-inflammatory compounds. Celastrol has been shown to have therapeutic potential in treating many inflammatory diseases; however, there is little information on its ability to attenuate IL-8 production in human monocytes and macrophages. Here, we determined the effects of celastrol on LPS-induced IL-8 release and its molecular mechanism. Celastrol treatment significantly reduced IL-8 release from LPS-activated human monocytes and monocyte-derived macrophages with IC50 values of 3.13 ? 0.03 ?M and 3.18 ? 0.05 ?M, respectively. Additionally, the inhibitory effect of celastrol on the production of IL-8 was related to the modulation of IL-8 mRNA levels. Pre-treatment with celastrol significantly inhibited IKK, I?B?, and p65 phosphorylation and also prevented I?B? degradation due to LPS activation. Collectively, these results demonstrate that celastrol attenuates the release of IL-8 from LPS-activated human monocytes and monocyte-derived macrophages and suggest that inhibition of NF-?B signalling activation is likely a mechanism for the attenuation. This anti-inflammatory effect further highlights the therapeutic potential of celastrol.

Download PDF

149 Downloads 1117 Views


a Faculty of Medicine, Thammasat University, Pathumthani 12121 Thailand
b Faculty of Medicine, Thammasat University, Pathumthani 12121 Thailand

* Corresponding author, E-mail: mnipapan@tu.ac.th, dr.nipapan@gmail.com

Received 10 Aug 2022, Accepted 8 May 2023